ClinicalTrials.gg
CompletedNCT04436744Updated Feb 2, 2023Results posted

A Study to Evaluate the Efficacy, Safety, and Pharmacokinetics of Giredestrant Plus Palbociclib Compared With Anastrozole Plus Palbociclib for Postmenopausal Women With Estrogen Receptor-Positive and HER2-Negative Untreated Early Breast Cancer (coopERA Breast Cancer)

A Phase 2 interventional study of Giredestrant and Anastrozole in Early Breast Cancer, sponsored by Hoffmann-La Roche. Completed at 65 sites in 11 countries. Open to female participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2023-02-02.

Sponsored by Hoffmann-La Roche · Phase 2, Interventional, and Treatment

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 2
Study type
Interventional
Enrollment
221
Allocation
Randomized
Ages
18 Years and older
Sex
Female
01

Where this study stands

Counted across the records on this site · 2026-11-16

Among 16 studies testing giredestrant in Breast Neoplasms — 4 open to participants now, 12 under way, 7 of them phase 3. giredestrant · Breast Neoplasms.

Enrollment
11th of 16
221 · median 302
Started
2020
with 2 others
Phase 2
7 of 16
2 open now
Registered
3rd of 16
by date
Lead sponsor
8 of 16
Hoffmann-La Roche

Among the 16 studies testing giredestrant in Breast Neoplasms, this one is the 11th largest by enrollment, is one of 3 that started in 2020, is one of 7 in phase 2, and was the 3rd registered.

Breast Neoplasms

14,832 studies on the registry are indexed under Breast Neoplasms; 3,320 are open to participants now.

Browse Breast Neoplasms studies →

Open to participants now

4 of the 16 studies testing giredestrant in Breast Neoplasms are open now, in 8 countries. Recruiting first, the newest first:

By country, each count listing its studies:

All 4 open studies →

About giredestrant

No approval found in the FDA or EMA files read. How studies give it is on its page →

Who these studies take

Of the 2,399 Breast Neoplasms studies recruiting now, 1,570 (65%) set no upper age limit and 592 (25%) stop at 75 or younger; 103 take children under 18; 215 take healthy volunteers.

This study: 18 Years and older · female · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 16 studies testing giredestrant in Breast Neoplasms, or all of them as a file.
02

Study summary

This is a randomized, multicenter, open-label, two-arm, Phase II study to evaluate the efficacy, safety, and pharmacokinetics of giredestrant versus anastrozole (in the window-of-opportunity phase) and giredestrant plus palbociclib compared with anastrozole plus palbociclib (in the neoadjuvant phase) in postmenopausal women with untreated, estrogen receptor (ER)-positive, human epidermal growth factor receptor-2 (HER2)-negative, early breast cancer.

The study consists of a screening period of up to 28 days, a window-of-opportunity phase for 14 days, followed by a neoadjuvant treatment phase for 16 weeks (four 28-day cycles), surgery, and an end of study visit (28 days after the final dose of study treatment).

03

Conditions studied

  • Early Breast Cancer

Browse trials for

04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
Female
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • women age ≥18 years
  • confirmed operable or inoperable invasive breast carcinoma
  • Candidate for treatment and considered appropriate for endocrine therapy
  • Willingness to undergo breast surgery after neoadjuvant treatment and to provide three mandatory tumor samples
  • Documented estrogen receptor (ER)-positive tumor in accordance to American Society of Clinical Oncology (ASCO)/College of American Pathologists (CAP) guidelines (Allison et al.2020), assessed locally and defined as ≥1% of tumor cells stained positive on the basis of the most recent tumor
  • Documented progesterone receptor status (positive or negative) as per local assessment
  • Documented human epidermal growth factor receptor-2 ()-negative tumor in accordance to 2018 ASCO/CAP guidelines (Wolff et al. 2018), assessed locally on the most recent tumor biopsy
  • Ki67 score ≥5% analyzed centrally or locally
  • Performance Status 0-1
  • Adequate organ function

Exclusion criteria

Exclusion Criteria:

  • Stage IV () breast cancer
  • Inflammatory breast cancer (cT4d)
  • Bilateral invasive breast cancer
  • History of invasive breast cancer, ductal carcinoma in situ or lobular carcinoma in situ and other within 5 years prior to screening
  • Previous systemic or local treatment for the primary breast cancer currently under investigation
  • History of any prior treatment with aromatase inhibitors (AIs), tamoxifen, selective estrogen receptor down regulator, or cyclin-dependent kinase 4 and 6 inhibitors
  • Major surgery within 4 weeks prior to randomization
  • Known history of liver disease consistent with Class B or C, including hepatitis
  • Other severe acute or chronic medical or psychiatric condition or laboratory abnormality that may increase the risk associated with study participation or product administration or may interfere with the interpretation of study results and, in the judgment of the investigator, would make the patient inappropriate for entry into this study
  • History of allergy to anastrozole, or palbociclib or any of its
  • Known issues with swallowing oral medication
  • History of documented hemorrhagic diathesis, coagulopathy, or thromboembolism
  • Active cardiac disease or history of cardiac dysfunction
  • Current treatment with medications that are well known to prolong the
  • Active inflammatory bowel disease or chronic diarrhea, short bowel syndrome, or major upper gastrointestinal surgery including gastric resection
  • Treatment with strong inhibitors or inducers within 14 days or 5 drug elimination half-lives prior to randomization
  • Known infection
  • Serious infection requiring oral or IV antibiotics, or other clinically significant infection within 14 days prior to screening
  • Any serious medical condition or abnormality in clinical laboratory tests that, in the investigator's judgment, precludes the patient's safe participation in and completion of the study
Terms in these criteria, in plain language(15)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Postmenopausal

Periods have stopped for good: usually no period for 12 months in a row without another medical reason, sometimes confirmed by a blood test (FSH).

Histologically or cytologically confirmed

The diagnosis was confirmed by looking at a sample under a microscope: tissue from a biopsy or surgery (histology), or cells from a fluid or needle sample (cytology).

Your pathology report is the document that shows this.

Adjuvant and neoadjuvant

Neoadjuvant treatment is given before the main treatment (usually surgery), often to shrink a tumor. Adjuvant treatment is given after it, to lower the chance of the cancer coming back.

Biopsy and archival tissue

A biopsy takes a small piece of tissue to examine. “Archival tissue” is a sample already taken, for example at diagnosis, and kept by the hospital.

Whether a stored sample will do depends on when it was taken, how much there is and what the study needs. Ask whether the study accepts your stored sample or needs a new biopsy.

HER2

HER2 is a protein, made from the ERBB2 gene, that drives the growth of some cancers. A study may look for a level of the protein, extra copies of the gene, or a particular change in it.

In breast cancer, protein tests are read as HER2-positive, HER2-low or HER2-negative; other cancers use their own rules. Check which test result the study requires.

ECOG performance status

A scale of how much an illness limits everyday activity. For people being assessed to join a study, scores run from 0 (fully active) to 4; lower is more active.

0
Fully active, no restrictions.
1
Limited in strenuous activity, but walking and able to do light work, such as housework or office work.
2
Walking and able to look after yourself, but unable to work; up and about more than half of waking hours.
3
Able to look after yourself only in part; in bed or a chair more than half of waking hours.
4
Unable to look after yourself at all; in bed or a chair all day.

Studies most often ask for 0–1 or 0–2. Your doctor gives the score; the WHO scale uses the same steps. The full scale also has 5, which records death.

Metastases

Cancer that has spread from where it began to other parts of the body. “Metastatic” cancer is cancer that has spread this way.

Cancer (malignancy)

Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.

Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.

Clinically significant

Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.

Child-Pugh class

A score of how well the liver works in people with liver disease such as cirrhosis: class A is mild, B moderate and C severe.

Investigational drug or device

A drug or device being studied in a clinical trial.

It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.

Excipients

The other ingredients in a medicine besides the active drug, such as fillers, colors or preservatives.

QT and QTc

On an ECG, the QT interval is the time the heart’s lower chambers take to activate electrically and recover in each beat. QTc is that time adjusted for heart rate (QTcF by Fridericia’s formula, QTcB by Bazett’s). Some medicines lengthen it, and a long QTc can raise the risk of a dangerous heart rhythm.

The study may name a correction formula and a limit in milliseconds, often around 450–480.

CYP3A (CYP3A4) inhibitors and inducers

CYP3A is a group of enzymes, mainly CYP3A4, in the liver and gut that break down many medicines. Some medicines, supplements and foods (grapefruit, St John’s wort) slow them down or speed them up, which changes how much of a study drug stays in the body.

Studies list them so they can be avoided or switched; bring a list of everything you take, including supplements.

HIV

The human immunodeficiency virus, which weakens the immune system.

Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.

05

Study design

Phase
Phase 2
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
None (open label)
Enrollment
221 participants (actual)

Study arms

  • Experimental
    Giredestrant + Palbociclib

    Drug: Giredestrant · Drug: Palbociclib · Procedure: Surgery

  • Active comparator
    Anastrozole + Palbociclib

    Drug: Anastrozole · Drug: Palbociclib · Procedure: Surgery

Interventions

  • During the window-of-opportunity phase (first 2 weeks) giredestrant will be taken orally once per day (QD) as a single agent. During the neoadjuvant treatment phase, giredestrant will be taken orally QD on Days 1-28 of each 28-day cycle for a total of 4 cycles, in combination with palbociclib.

    Also known as: GDC-9545, RO7197597, RG6171

  • During the window-of-opportunity phase (first 2 weeks), anastrozole 1 mg will be taken orally QD as a single agent. During the neoadjuvant treatment phase, anastrozole 1 mg will be taken orally QD on Days 1-28 of each 28-day cycle for a total of 4 cycles, in combination with palbociclib.

  • During the neoadjuvant treatment phase, palbociclib 125 mg will be taken orally QD on Days 1-21 of a 28-day cycle for a total of 4 cycles.

  • ProcedureSurgery

    Surgery must be performed within a maximum of 14 days after the final cycle in the neoadjuvant treatment phase and ideally should occur as soon as possible after the last dose of study treatment.

06

What researchers measure

Primary outcomes

  1. Relative Percent Change in Ki67 Scores From Baseline to Week 2

    Ki67 is a proliferation biomarker with prognostic value in ER-positive breast cancer. Ki67 scores were centrally assessed with immunohistochemistry and defined as a percentage of positively stained tumor cell nuclei among the total number of tumor cells assessed, with a potential range of 0-100%. A score of 0% indicates no tumor cell nuclei with Ki67 staining and a score of 100% indicates all tumor cell nuclei are positively stained with Ki67. The relative percentage change was calculated using Ki67 scores at Baseline and Week 2. Relative Percent Change was defined as Week 2 Ki67 percentage score/Baseline Ki67 percentage score\*100. A smaller value of relative percentage change indicates improvement.

    Time frame: Baseline, Week 2

Secondary outcomes

  1. Overall Response Rate (ORR) by Ultrasound as Determined by the Investigator

    ORR was defined as the percentage of participants with a complete response (CR) or partial response (PR), as determined by the investigator according to Modified Response Evaluation Criteria in Solid Tumors (mRECIST). Ultrasound and clinical exam were used to assess response. CR per mRECIST was defined as the disappearance of all target lesions. PR per mRECIST was defined as at least 30% decrease in the sum of diameters of target lesions, taking as reference the baseline sum of diameters. An estimate of ORR and its 95% confidence interval (CI) was calculated using the Clopper-Pearson method.

    Time frame: Baseline up to Cycle 4 Day 1 (each cycle is 28 days)

  2. Complete Cell Cycle Arrest (CCCA) Rate at Week 2

    CCCA was defined as the percentage of participants with centrally assessed Ki67 scores ≤2.7%. The CCCA rate at Week 2 was summarized.

    Time frame: Week 2

  3. Number of Participants With Adverse Events (AEs) With Severity Determined in Accordance With National Cancer Institute Common Terminology Criteria for Adverse Events, Version 5.0 (NCI CTCAE v5.0)

    AE is any untoward medical occurrence in clinical investigation participant administered a pharmaceutical product, regardless of causal attribution. An AE can therefore be any unfavorable \& unintended sign, symptom/disease temporally associated with use of a medicinal product, whether or not related to medicinal product. Preexisting conditions which worsen during a study also considered as AEs. Severity of AEs was determined per NCI CTCAE v5.0. Grade 1: Mild; asymptomatic/mild symptoms; clinical/diagnostic observations only; or intervention not indicated; Grade 2: Moderate; minimal, local/non-invasive intervention indicated; or limiting age-appropriate instrumental activities of daily living; Grade 3: Severe/medically significant, but not immediately life-threatening: hospitalization/prolongation of hospitalization indicated; disabling/limiting self-care activities of daily living; Grade 4: Life-threatening consequences/urgent intervention indicated; Grade 5: Death related to AE.

    Time frame: From baseline up to 28 days after the last dose (up to approximately 24 weeks)

  4. Change From Baseline in Respiratory Rate Over Time

    Respiratory rate was measured while the participant was in a seated position.

    Time frame: Baseline; Cycles 1-2: Day 1 and Day 15; Cycles 3-4: Day 1; day of surgery (up to 2 weeks after the final dose of study treatment [approximately Week 18]) and end of study (up to approximately 24 weeks)

  5. Change From Baseline in Pulse Rate Over Time

    Pulse rate was measured while the participant was in a seated position.

    Time frame: Baseline; Cycles 1-2: Day 1 and Day 15; Cycles 3-4: Day 1; day of surgery (up to 2 weeks after the final dose of study treatment [approximately Week 18]) and end of study (up to approximately 24 weeks)

  6. Change From Baseline in Systolic Blood Pressure Over Time

    Systolic blood pressure was measured while the participant was in a seated position.

    Time frame: Baseline; Cycles 1-2: Day 1 and Day 15; Cycles 3-4: Day 1; day of surgery (up to 2 weeks after the final dose of study treatment [approximately Week 18]) and end of study (up to approximately 24 weeks)

  7. Change From Baseline in Diastolic Blood Pressure Over Time

    Diastolic blood pressure was measured while the participant was in a seated position.

    Time frame: Baseline; Cycles 1-2: Day 1 and Day 15; Cycles 3-4: Day 1; day of surgery (up to 2 weeks after the final dose of study treatment [approximately Week 18]) and end of study (up to approximately 24 weeks)

  8. Change From Baseline in Body Temperature Over Time

    Time frame: Baseline; Cycles 1-2: Day 1 and Day 15; Cycles 3-4: Day 1; day of surgery (up to 2 weeks after the final dose of study treatment [approximately Week 18]) and end of study (up to approximately 24 weeks)

  9. Number of Participants With Shifts in Hematology Test Parameters From NCI-CTCAE Grade 0-2 at Baseline to Grade 3-4 at Post-baseline

    Hematology test parameters were measured per NCI CTCAE v5.0. Grade 0 is normal, and Grades 1 to 4 represent worsening levels of the parameter outside of the normal range in the specified direction of the abnormality (high and low are above and below the range, respectively). Number of participants with shift in the hematology values from grade 0-2 at baseline to grade 3-4 at post-baseline were reported. A marked reference range for hemoglobin 12.3-15.3 grams per deciliter (g/dL), lymphocytes absolute (Abs) 1.0-4.8 10\^3/microliters (uL), neutrophils total, Abs, 1.8-8.5 10\^3/uL, platelet 100-450 10\^9/liter (L), total leukocyte 4.4-11 10\^9/L.

    Time frame: From baseline up to 28 days after the last dose (up to approximately 24 weeks)

  10. Number of Participants With Shifts in Blood Chemistry Parameters From NCI-CTCAE Grade 0-2 at Baseline to Grade 3-4 at Post-baseline

    Blood chemistry parameters were measured per NCI CTCAE v5.0. Grade 0=normal, and Grades 1 to 4 represent worsening levels of parameter outside of normal range in the specified direction of abnormality (high \& low are above \& below the range, respectively). Number of participants with shift in blood chemistry values from grade 0-2 at baseline to grade 3-4 at post-baseline were reported. Marked reference range for albumin 32-45 grams per liter (g/L), alkaline phosphatase 20-130 units per liter (U/L), serum glutamic pyruvic transaminase (SGPT)/ alanine transaminase (ALT) 4-36 U/L, serum glutamic oxaloacetic transaminase (SGOT)/ aspartate transaminase (AST) 8-33 U/L, calcium 2.3-2.74 millimoles per liter (mmol/L), cholesterol 3.88-6.47mmol/L, creatinine 6-12 milligrams per liter (mg/L), glucose 3.9-6.1 mmol/L, potassium 3.5-5.0 mmol/L, sodium 135-147 mmol/L, bilirubin 2-21 micromoles per liter (μmol/L), triglycerides 0.11-2.15 mmol/L, \& uric acid 2.7-7.3 milligrams per deciliter (mg/dL).

    Time frame: From baseline up to 28 days after the last dose (up to approximately 24 weeks)

  11. Plasma Concentration of Giredestrant at Specified Timepoints

    Time frame: Window of Opportunity Phase: Day 1 (3 hours Postdose) and Day 15 (Predose) during Cycle 0 (the 15-day period in Window of Opportunity Phase is called Cycle 0 for PK analysis); Neoadjuvant Phase: Cycle 2 Day 1, Predose

07

Results

Posted Feb 2, 2023

Participant flow

Participants took part in this study at 64 investigative sites in Australia, Brazil, Germany, Hungary, Korea, Poland, Russia, Spain, Taiwan, the United States, and Ukraine, from 4 September 2020 to 24 November 2021.

Participant flow — Overall Study
MilestoneGiredestrant + PalbociclibAnastrozole + Palbociclib
Started112109
Completed10898
Not completed411
Withdrew: Adverse event11
Withdrew: Death10
Withdrew: Lost to follow-up02
Withdrew: Physician decision01
Withdrew: Progressive disease04
Withdrew: Protocol deviation11
Withdrew: Withdrawal by subject12

Outcome measures

PrimaryRelative Percent Change in Ki67 Scores From Baseline to Week 2

Ki67 is a proliferation biomarker with prognostic value in ER-positive breast cancer. Ki67 scores were centrally assessed with immunohistochemistry and defined as a percentage of positively stained tumor cell nuclei among the total number of tumor cells assessed, with a potential range of 0-100%. A score of 0% indicates no tumor cell nuclei with Ki67 staining and a score of 100% indicates all tumor cell nuclei are positively stained with Ki67. The relative percentage change was calculated using Ki67 scores at Baseline and Week 2. Relative Percent Change was defined as Week 2 Ki67 percentage score/Baseline Ki67 percentage score\*100. A smaller value of relative percentage change indicates improvement.

Time frame:
Baseline, Week 2
Reported as:
Geometric mean · percent change
Relative Percent Change in Ki67 Scores From Baseline to Week 2
percent changeGiredestrant + PalbociclibAnastrozole + Palbociclib
Relative Percent Change in Ki67 Scores From Baseline to Week 225 (20 to 30)33 (27 to 41)
Statistical analysis
  • Giredestrant + Palbociclib vs Anastrozole + Palbociclib · t-test, 2 sided · p = 0.0433
SecondaryOverall Response Rate (ORR) by Ultrasound as Determined by the Investigator

ORR was defined as the percentage of participants with a complete response (CR) or partial response (PR), as determined by the investigator according to Modified Response Evaluation Criteria in Solid Tumors (mRECIST). Ultrasound and clinical exam were used to assess response. CR per mRECIST was defined as the disappearance of all target lesions. PR per mRECIST was defined as at least 30% decrease in the sum of diameters of target lesions, taking as reference the baseline sum of diameters. An estimate of ORR and its 95% confidence interval (CI) was calculated using the Clopper-Pearson method.

Time frame:
Baseline up to Cycle 4 Day 1 (each cycle is 28 days)
Reported as:
Number · percentage of participants
Overall Response Rate (ORR) by Ultrasound as Determined by the Investigator
percentage of participantsGiredestrant + PalbociclibAnastrozole + Palbociclib
Overall Response Rate (ORR) by Ultrasound as Determined by the Investigator50.0 (40.40 to 59.60)49.1 (39.33 to 58.87)
Statistical analysis
  • Giredestrant + Palbociclib vs Anastrozole + Palbociclib · Cochran-Mantel-Haenszel · p = 0.8272 · Difference in overall response rates: -0.93 · 95% CI -14.66 to 12.81
SecondaryComplete Cell Cycle Arrest (CCCA) Rate at Week 2

CCCA was defined as the percentage of participants with centrally assessed Ki67 scores ≤2.7%. The CCCA rate at Week 2 was summarized.

Time frame:
Week 2
Reported as:
Number · percentage of participants
Complete Cell Cycle Arrest (CCCA) Rate at Week 2
percentage of participantsGiredestrant + PalbociclibAnastrozole + Palbociclib
Complete Cell Cycle Arrest (CCCA) Rate at Week 219.612.8
Statistical analysis
  • Giredestrant + Palbociclib vs Anastrozole + Palbociclib · Difference in rate: 6.86 · 95% CI -4.25 to 17.97
SecondaryNumber of Participants With Adverse Events (AEs) With Severity Determined in Accordance With National Cancer Institute Common Terminology Criteria for Adverse Events, Version 5.0 (NCI CTCAE v5.0)

AE is any untoward medical occurrence in clinical investigation participant administered a pharmaceutical product, regardless of causal attribution. An AE can therefore be any unfavorable \& unintended sign, symptom/disease temporally associated with use of a medicinal product, whether or not related to medicinal product. Preexisting conditions which worsen during a study also considered as AEs. Severity of AEs was determined per NCI CTCAE v5.0. Grade 1: Mild; asymptomatic/mild symptoms; clinical/diagnostic observations only; or intervention not indicated; Grade 2: Moderate; minimal, local/non-invasive intervention indicated; or limiting age-appropriate instrumental activities of daily living; Grade 3: Severe/medically significant, but not immediately life-threatening: hospitalization/prolongation of hospitalization indicated; disabling/limiting self-care activities of daily living; Grade 4: Life-threatening consequences/urgent intervention indicated; Grade 5: Death related to AE.

Time frame:
From baseline up to 28 days after the last dose (up to approximately 24 weeks)
Reported as:
Count of participants · Participants
Number of Participants With Adverse Events (AEs) With Severity Determined in Accordance With National Cancer Institute Common Terminology Criteria for Adverse Events, Version 5.0 (NCI CTCAE v5.0)
ParticipantsGiredestrant + PalbociclibAnastrozole + Palbociclib
AEs10498
Grade 11920
Grade 23531
Grade 34545
Grade 442
Grade 510
SecondaryChange From Baseline in Respiratory Rate Over Time

Respiratory rate was measured while the participant was in a seated position.

Time frame:
Baseline; Cycles 1-2: Day 1 and Day 15; Cycles 3-4: Day 1; day of surgery (up to 2 weeks after the final dose of study treatment [approximately Week 18]) and end of study (up to approximately 24 weeks)
Reported as:
Mean · breath/minute (min)
Change From Baseline in Respiratory Rate Over Time
breath/minute (min)Giredestrant + PalbociclibAnastrozole + Palbociclib
Baseline17.16 ± 2.2717.10 ± 2.05
Change from Baseline at Cycle 1 Day 10.30 ± 2.120.26 ± 1.50
Change from Baseline at Cycle 1 Day 15-0.01 ± 1.49-0.06 ± 1.36
Change from Baseline at Cycle 2 Day 1-0.10 ± 1.830.16 ± 1.34
Change from Baseline at Cycle 2 Day 15-0.24 ± 1.71-0.03 ± 1.64
Change from Baseline at Cycle 3 Day 10.07 ± 1.580.01 ± 1.61
Change from Baseline at Cycle 4 Day 1-0.04 ± 1.710.01 ± 1.53
Change from Baseline at Day of Surgery0.04 ± 1.72-0.02 ± 1.69
Change from Baseline at End of Study-0.26 ± 1.650.01 ± 1.42
SecondaryChange From Baseline in Pulse Rate Over Time

Pulse rate was measured while the participant was in a seated position.

Time frame:
Baseline; Cycles 1-2: Day 1 and Day 15; Cycles 3-4: Day 1; day of surgery (up to 2 weeks after the final dose of study treatment [approximately Week 18]) and end of study (up to approximately 24 weeks)
Reported as:
Mean · beats/min
Change From Baseline in Pulse Rate Over Time
beats/minGiredestrant + PalbociclibAnastrozole + Palbociclib
Baseline75.86 ± 10.6776.73 ± 9.85
Change from Baseline at Cycle 1 Day 1-4.74 ± 9.07-1.96 ± 9.43
Change from Baseline at Cycle 1 Day 15-6.02 ± 12.02-1.47 ± 8.15
Change from Baseline at Cycle 2 Day 1-5.20 ± 10.26-1.11 ± 10.79
Change from Baseline at Cycle 2 Day 15-7.68 ± 11.03-1.95 ± 8.64
Change from Baseline at Cycle 3 Day 1-5.47 ± 11.61-0.81 ± 10.83
Change from Baseline at Cycle 4 Day 1-5.67 ± 9.79-1.11 ± 10.62
Change from Baseline at Day of Surgery-4.14 ± 11.25-1.26 ± 10.46
Change from Baseline at End of Study-0.61 ± 10.741.59 ± 10.44
SecondaryChange From Baseline in Systolic Blood Pressure Over Time

Systolic blood pressure was measured while the participant was in a seated position.

Time frame:
Baseline; Cycles 1-2: Day 1 and Day 15; Cycles 3-4: Day 1; day of surgery (up to 2 weeks after the final dose of study treatment [approximately Week 18]) and end of study (up to approximately 24 weeks)
Reported as:
Mean · millimeters of mercury (mmHg)
Change From Baseline in Systolic Blood Pressure Over Time
millimeters of mercury (mmHg)Giredestrant + PalbociclibAnastrozole + Palbociclib
Baseline135.63 ± 14.13130.03 ± 16.43
Change from Baseline at Cycle 1 Day 1-0.82 ± 11.111.12 ± 13.65
Change from Baseline at Cycle 1 Day 15-2.55 ± 14.010.23 ± 15.85
Change from Baseline at Cycle 2 Day 1-2.08 ± 14.130.28 ± 14.43
Change from Baseline at Cycle 2 Day 15-4.25 ± 15.370.16 ± 16.49
Change from Baseline at Cycle 3 Day 1-2.66 ± 16.950.33 ± 15.81
Change from Baseline at Cycle 4 Day 1-1.29 ± 15.30-0.25 ± 14.17
Change from Baseline at Day of Surgery-2.35 ± 13.791.51 ± 15.24
Change from Baseline at End of Study-5.38 ± 13.98-1.67 ± 16.20
SecondaryChange From Baseline in Diastolic Blood Pressure Over Time

Diastolic blood pressure was measured while the participant was in a seated position.

Time frame:
Baseline; Cycles 1-2: Day 1 and Day 15; Cycles 3-4: Day 1; day of surgery (up to 2 weeks after the final dose of study treatment [approximately Week 18]) and end of study (up to approximately 24 weeks)
Reported as:
Mean · mmHg
Change From Baseline in Diastolic Blood Pressure Over Time
mmHgGiredestrant + PalbociclibAnastrozole + Palbociclib
Baseline80.40 ± 8.8478.49 ± 9.55
Change from Baseline at Cycle 1 Day 1-2.42 ± 7.770.39 ± 8.13
Change from Baseline at Cycle 1 Day 15-4.80 ± 8.58-2.42 ± 8.71
Change from Baseline at Cycle 2 Day 1-4.79 ± 10.08-0.76 ± 8.80
Change from Baseline at Cycle 2 Day 15-5.64 ± 9.24-1.32 ± 9.64
Change from Baseline at Cycle 3 Day 1-5.25 ± 8.51-0.16 ± 9.52
Change from Baseline at Cycle 4 Day 1-4.35 ± 9.31-2.57 ± 9.50
Change from Baseline at Day of Surgery-4.93 ± 8.72-2.15 ± 9.58
Change from Baseline at End of Study-2.73 ± 8.37-2.52 ± 12.11
SecondaryChange From Baseline in Body Temperature Over Time
Time frame:
Baseline; Cycles 1-2: Day 1 and Day 15; Cycles 3-4: Day 1; day of surgery (up to 2 weeks after the final dose of study treatment [approximately Week 18]) and end of study (up to approximately 24 weeks)
Reported as:
Mean · Celsius (C)
Change From Baseline in Body Temperature Over Time
Celsius (C)Giredestrant + PalbociclibAnastrozole + Palbociclib
Baseline36.35 ± 0.4136.45 ± 0.38
Change from Baseline at Cycle 1 Day 10.07 ± 0.390.04 ± 0.36
Change from Baseline at Cycle 1 Day 150.01 ± 0.41-0.01 ± 0.43
Change from Baseline at Cycle 2 Day 10.03 ± 0.40-0.04 ± 0.52
Change from Baseline at Cycle 2 Day 15-0.03 ± 0.37-0.12 ± 0.47
Change from Baseline at Cycle 3 Day 1-0.04 ± 0.420.01 ± 0.39
Change from Baseline at Cycle 4 Day 1-0.03 ± 0.37-0.08 ± 0.38
Change from Baseline at Day of Surgery0.06 ± 0.39-0.01 ± 0.38
Change from Baseline at End of Study0.05 ± 0.39-0.04 ± 0.48
SecondaryNumber of Participants With Shifts in Hematology Test Parameters From NCI-CTCAE Grade 0-2 at Baseline to Grade 3-4 at Post-baseline

Hematology test parameters were measured per NCI CTCAE v5.0. Grade 0 is normal, and Grades 1 to 4 represent worsening levels of the parameter outside of the normal range in the specified direction of the abnormality (high and low are above and below the range, respectively). Number of participants with shift in the hematology values from grade 0-2 at baseline to grade 3-4 at post-baseline were reported. A marked reference range for hemoglobin 12.3-15.3 grams per deciliter (g/dL), lymphocytes absolute (Abs) 1.0-4.8 10\^3/microliters (uL), neutrophils total, Abs, 1.8-8.5 10\^3/uL, platelet 100-450 10\^9/liter (L), total leukocyte 4.4-11 10\^9/L.

Time frame:
From baseline up to 28 days after the last dose (up to approximately 24 weeks)
Reported as:
Count of participants · Participants
Number of Participants With Shifts in Hematology Test Parameters From NCI-CTCAE Grade 0-2 at Baseline to Grade 3-4 at Post-baseline
ParticipantsGiredestrant + PalbociclibAnastrozole + Palbociclib
Hemoglobin: Low31
Hemoglobin: High01
Lymphocytes Abs: Low92
Lymphocytes Abs: High12
Neutrophils, Total, Abs: Low4338
Platelet: Low00
Total Leukocyte Count: Low1511
Total Leukocyte Count: High00
SecondaryNumber of Participants With Shifts in Blood Chemistry Parameters From NCI-CTCAE Grade 0-2 at Baseline to Grade 3-4 at Post-baseline

Blood chemistry parameters were measured per NCI CTCAE v5.0. Grade 0=normal, and Grades 1 to 4 represent worsening levels of parameter outside of normal range in the specified direction of abnormality (high \& low are above \& below the range, respectively). Number of participants with shift in blood chemistry values from grade 0-2 at baseline to grade 3-4 at post-baseline were reported. Marked reference range for albumin 32-45 grams per liter (g/L), alkaline phosphatase 20-130 units per liter (U/L), serum glutamic pyruvic transaminase (SGPT)/ alanine transaminase (ALT) 4-36 U/L, serum glutamic oxaloacetic transaminase (SGOT)/ aspartate transaminase (AST) 8-33 U/L, calcium 2.3-2.74 millimoles per liter (mmol/L), cholesterol 3.88-6.47mmol/L, creatinine 6-12 milligrams per liter (mg/L), glucose 3.9-6.1 mmol/L, potassium 3.5-5.0 mmol/L, sodium 135-147 mmol/L, bilirubin 2-21 micromoles per liter (μmol/L), triglycerides 0.11-2.15 mmol/L, \& uric acid 2.7-7.3 milligrams per deciliter (mg/dL).

Time frame:
From baseline up to 28 days after the last dose (up to approximately 24 weeks)
Reported as:
Count of participants · Participants
Number of Participants With Shifts in Blood Chemistry Parameters From NCI-CTCAE Grade 0-2 at Baseline to Grade 3-4 at Post-baseline
ParticipantsGiredestrant + PalbociclibAnastrozole + Palbociclib
Albumin: low10
Alkaline Phosphatase: High00
SGPT/ALT: High15
SGOT/AST: High13
Calcium: Low03
Calcium: High00
Cholesterol: High00
Creatinine: High01
Glucose: Low00
Potassium: Low00
Potassium: High00
Sodium: Low00
Sodium: High00
Bilirubin: High00
Triglycerides: High10
Uric Acid: High2122
SecondaryPlasma Concentration of Giredestrant at Specified Timepoints
Time frame:
Window of Opportunity Phase: Day 1 (3 hours Postdose) and Day 15 (Predose) during Cycle 0 (the 15-day period in Window of Opportunity Phase is called Cycle 0 for PK analysis); Neoadjuvant Phase: Cycle 2 Day 1, Predose
Reported as:
Geometric mean · nanograms per milliliters (ng/mL)
Plasma Concentration of Giredestrant at Specified Timepoints
nanograms per milliliters (ng/mL)Giredestrant + Palbociclib
Window of Opportunity Phase: Cycle 0 Day 1, 3-h Postdose81.8 ± 284
Window of Opportunity Phase: Cycle 0 Day 15, Predose137 ± 61.1
Neoadjuvant Phase: Cycle 2 Day 1, Predose130 ± 122

Adverse events

Collected over From baseline up to 28 days after the last dose (up to approximately 24 weeks). Non-serious events are listed at a 5% frequency threshold.

Adverse event summary by group
GroupDeathsSeriousOther
Giredestrant + Palbociclib1/112 (0.9%)5/112 (4.5%)99/112 (88.4%)
Anastrozole + Palbociclib0/109 (0%)2/109 (1.8%)93/109 (85.3%)
Most frequent serious events
Most frequent serious events
EventGiredestrant + PalbociclibAnastrozole + Palbociclib
Procedural painInjury, poisoning and procedural complications0/1121/109
HypoxiaRespiratory, thoracic and mediastinal disorders0/1121/109
Myocardial infarctionCardiac disorders1/1120/109
PyrexiaGeneral disorders1/1120/109
COVID-19Infections and infestations1/1120/109
Hip fractureInjury, poisoning and procedural complications1/1120/109
Uterine perforationInjury, poisoning and procedural complications1/1120/109
Most frequent other events
Showing 10 of 21
Most frequent other events
EventGiredestrant + PalbociclibAnastrozole + Palbociclib
NeutropeniaBlood and lymphatic system disorders46/11244/109
AstheniaGeneral disorders25/11227/109
Neutrophil count decreasedInvestigations26/11224/109
ArthralgiaMusculoskeletal and connective tissue disorders12/11221/109
DiarrhoeaGastrointestinal disorders8/11218/109
FatigueGeneral disorders10/11218/109
LeukopeniaBlood and lymphatic system disorders14/11216/109
Hot flushVascular disorders16/11216/109
NauseaGastrointestinal disorders16/11213/109
White blood cell count decreasedInvestigations14/11210/109

Baseline characteristics

Intent-to-Treat (ITT) population included all randomized participants.

Age, Continuous
Age, Continuous(years)Giredestrant + PalbociclibAnastrozole + PalbociclibTotal
Mean63.1 ± 7.962.4 ± 9.362.8 ± 8.6
Sex: Female, Male
Sex: Female, Male(Participants)Giredestrant + PalbociclibAnastrozole + PalbociclibTotal
Female112109221
Male000
Ethnicity (NIH/OMB)
Ethnicity (NIH/OMB)(Participants)Giredestrant + PalbociclibAnastrozole + PalbociclibTotal
Hispanic or Latino161127
Not Hispanic or Latino9598193
Unknown or Not Reported101
Race (NIH/OMB)
Race (NIH/OMB)(Participants)Giredestrant + PalbociclibAnastrozole + PalbociclibTotal
American Indian or Alaska Native000
Asian6915
Native Hawaiian or Other Pacific Islander000
Black or African American213
White10094194
More than one race000
Unknown or Not Reported459
Ki67 Scores
Ki67 Scores(percent Ki67 score)Giredestrant + PalbociclibAnastrozole + PalbociclibTotal
Mean37.92 (6.6 to 96.3)41.66 (7.8 to 98.9)39.76 (6.6 to 98.9)
08

Study locations

65 sites
  • UCLA - Burbank
    Burbank, California 91505, United States
  • UCLA - Laguna Hills
    Laguna Hills, California 92653, United States
  • UCLA Hematology/Oncology-San Luis Obispo
    San Luis Obispo, California 93401, United States
  • UCLA Hematology Oncology-Santa Monica
    Santa Monica, California 90404, United States
  • Torrance Memorial Physician Network/Cancer Care
    Torrance, California 90505, United States
  • Orlando Health Inc.
    Orlando, Florida 32806, United States
  • SCRI Florida Cancer Specialists East
    West Palm Beach, Florida 33401, United States
  • Saint Barnabas Medical Center Cancer Center
    Livingston, New Jersey 07039, United States
  • Tennessee Oncology; Sarah Cannon Research Institute
    Nashville, Tennessee 37203, United States
  • Univ of Wisconsin-Madison; Clinical Science Center
    Madison, Wisconsin 53762, United States
  • Macquarie University Hospital
    Macquarie Park, New South Wales 2109, Australia
  • Westmead Hospital; Medical Oncology and Pallative Care
    Westmead, New South Wales 2145, Australia
  • Hospital do Cancer de Pernambuco - HCP
    Recife, PE 50040-000, Brazil
  • Santa Casa de Misericordia de Porto Alegre
    Porto Alegre, RS 90050-170, Brazil
  • Clinica de Pesquisa e Centro de Estudos em Oncologia Ginecologica e Mamaria Ltda
    Sao Paulo, SP 01317-001, Brazil
  • Núcleo de Pesquisa São Camilo; ONCOLOGIA CLINICA / QUIMIOTERAPIA
    Sao Paulo, SP 04014-002, Brazil
  • Universitätsklinikum Dresden
    Dresden, 01307, Germany
  • LUISENKRANKENHAUS; Senological Oncology
    Düsseldorf, 40235, Germany
  • UNIVERSITATSKLINIKUM ERLANGEN; Department of Gynecology and Obstetrics
    Erlangen, 91054, Germany
  • Bacs-Kiskun Megyei Korhaz, SZTE AOK Oktato Korhaza, Onkoradiologiai Kozpont; Onkoradiologiai Kozpont
    Kecskemet, 6000, Hungary
  • Tolna Megyei Kórház, Onkológia
    Szekszárd, 7100, Hungary
  • National Cancer Center; Medical Oncology
    Gyeonggi-do, 410-769, Korea, Republic of
  • Seoul National University Hospital
    Seoul, 03080, Korea, Republic of
  • Asan Medical Center
    Seoul, 05505, Korea, Republic of
  • Severance Hospital; Internal Medicine
    Seoul, 110-744, Korea, Republic of
  • Samsung Medical Center
    Seoul, 135-710, Korea, Republic of
  • The Catholic University of Korea Seoul St. Mary's Hospital
    Seoul, 6591, Korea, Republic of
  • Szpital Morski Im. Pck; Oncology & Radiotherapy Dept
    Gdynia, 81-519, Poland
  • COZL Oddzial Onkologii Klinicznej z pododdzialem Chemioterapii Dziennej
    Lublin, 20-090, Poland
  • Centrum Onkologii - Inst.Im. Marii Sklodowskiej-Curie; Oncology
    Warszawa, 02-781, Poland
  • DOLNOSLASKIE CENTRUM ONKOLOGII; Oddzial Chirurgii Piersi
    Wrocław, 53-413, Poland
  • Moscow City Oncology Hospital #62
    Moscovskaya Oblast, Moskovskaja Oblast 143423, Russian Federation
  • Private Healthcare Institution Clinical Hospital RZhD Medicine
    St. Petersburg, Sankt Petersburg 195271, Russian Federation
  • Republican Clinical Oncology Dispensary of Ministry of Healthcare of Tatarstan Republic
    Kazan, Tatarstan 420029, Russian Federation
  • Filial #1 Regional Oncology Dispensary of Nizhniy Novgorod
    Nizhny Novgorod, 603081, Russian Federation
  • S-Pb clinical scientific practical center of specialized kinds of medical care (oncological)
    Saint-Petersburg, 197758, Russian Federation
  • FSI "SRC of Oncology n. a. N.N.Petrov of Rosmedtekhnologiy"
    St. Petersburg, 197758, Russian Federation
  • Institutio Catalan De Oncologia
    Badalona, Barcelona 08916, Spain
  • Complejo Hospitalario de Althaia; Servicio de Oncologia
    Manresa, Barcelona 08243, Spain
  • Hospital de Jerez de la Frontera; Servicio de Oncologia
    Jerez de La Frontera, Cadiz 11407, Spain
  • Hospital Universitari Arnau de Vilanova
    Lleida, Lerida 25198, Spain
  • Hospital Universitario Puerta de Hierro Majadahonda
    Majadahonda, Madrid 28222, Spain
  • Hospital Universitari Sant Joan de Reus; Planta baja, color lila
    Reus, Tarragona 43204, Spain
  • Hospital Universitario de Canarias;servicio de Oncologia
    La Laguna, Tenerife 38320, Spain
  • Hospital de la Santa Creu i Sant Pau
    Barcelona, 08025, Spain
  • Hospital Universitario Quirón Dexeus
    Barcelona, 08028, Spain
  • Hospital Universitari Vall d'Hebron
    Barcelona, 08035, Spain
  • Hospital Universitario Virgen de las Nieves : Hospital General
    Granada, 18014, Spain
  • Hospital Clinico San Cecilio
    Granada, 18016, Spain
  • Hospital Universitario Lucus Augusti
    Lugo, 27003, Spain
  • Hospital Universitario La Paz
    Madrid, 280146, Spain
  • Fundación Jimenez Díaz
    Madrid, 28040, Spain
  • Hosp Univ Fundacion Alcorcon
    Madrid, 28922, Spain
  • Hospital Universitario Virgen de La Arrixaca
    Murcia, 30120, Spain
  • Hospital de Navarra; Servicio de Oncologia
    Navarra, 31008, Spain
  • Hospital Universitario Virgen Macarena
    Sevilla, 41009, Spain
  • Hospital General Universitario de Valencia
    Valencia, 46014, Spain
  • National Cheng Kung Uni Hospital; Surgery
    Tainan, 704, Taiwan
  • National Taiwan Uni Hospital; General Surgery
    Taipei, 100, Taiwan
  • Regional Oncology Center of Kharkiv Regional Council; Department of Soft Tissues and Breast Cancer
    Kharkiv, Kharkiv Governorate 61070, Ukraine
  • Odesa Regional Clinical Hospital; Department of Thoracic Surgery
    Odesa, Kharkiv Governorate 65025, Ukraine
  • Khmelnytsky Regional Antitumor Center; Department of Breast, Skin, Soft Tissues and Bones Tumors
    Khmelnytskyi, Podolia Governorate 29009, Ukraine
  • Municipal institution Dnipropetrovsk City Multifield Clinical Hospital #4; dept. of Chemotherapy
    Dnipropetrovsk, 49102, Ukraine
  • ME Kryviy Rih Oncology Dispensary of Dnipropetrovs'k Regional Council; Chemotherapy Department
    Kryvyi Rih, 50048, Ukraine
  • Kyiv Regional Oncological Dispensary
    Kyiv, 04107, Ukraine
09

References and documents

Study documents

PDFs hosted by the registry, ClinicalTrials.gov.

Individual participant data

Plan to share: Yes — Qualified researchers may request access to individual patient level data through the request platform (www.vivli.org). Further details on Roche's criteria for eligible studies are available here (https://vivli.org/ourmember/roche/). For further details on Roche's Global Policy on Sharing of Clinical Study Information and how to request access to related clinical study documents, see here (https://www.roche.com/research_and_development/who_we_are_how_we_work/clinical_trials/our_commitment_to_data_sharing.htm).

10

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Ran from Sep 2020 to primary completion in Jul 2021, 10 months.

Results were first posted in Feb 2023, 1 year 6 months after primary completion. A results delay was requested in Jun 2022.

Of 232 industry-sponsored phase 2 interventional studies under Breast Neoplasms, half reached primary completion within 34 months of starting (the median), counting those still running; a quarter within 22 and three quarters within 53. This study's 10 months is below that.

Counting every sponsor, half of 1,302 studies reached it within 51 months; a quarter within 30 and three quarters within 82.

How these figures are worked out, and which studies are left out of them.

Registered
Jun 16, 2020
First posted
Jun 18, 2020
StartActual
Sep 4, 2020
Primary completionActual
Jul 6, 2021
CompletionActual
Nov 24, 2021
Results delay requested
Jun 23, 2022
Results first posted
Feb 2, 2023
Last update
Feb 2, 2023
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Feb 2, 2023, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
11

Registry details

Key details

Study ID
NCT04436744
Lead sponsor
Hoffmann-La Roche
Responsible party
Sponsor
First posted
Jun 18, 2020
Start date
Sep 4, 2020
Primary completion
Jul 6, 2021
Completion
Nov 24, 2021
Results posted
Feb 2, 2023
Last update
Feb 2, 2023

Study contacts

Clinical Trials
study director · Hoffmann-La Roche

Oversight

Data monitoring committee
No
FDA-regulated drug
Yes
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Jan 2023. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Giredestrant

Start the discussion